Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Carbidopa, Levodopa, And Entacapone
Brand Name
Carbidopa, Levodopa, And Entacapone
Generic Name
Carbidopa, Levodopa, And Entacapone
Active Ingredient
CarbidopaCategory
Aromatic Amino Acid [EPC]
Variants
6
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Carbidopa, Levodopa, And Entacapone, you must consult a qualified healthcare professional.
| 18.75 mg/1 | TABLET, FILM COATED | ORAL | 0781-5625 |
| 50 mg/1 | TABLET, FILM COATED | ORAL | 0781-5669 |
| 37.5 mg/1 | TABLET, FILM COATED | ORAL | 0781-5654 |
Detailed information about Carbidopa, Levodopa, And Entacapone
Carbidopa is an aromatic amino acid decarboxylation inhibitor primarily used as an adjunct to levodopa in the treatment of Parkinson's disease symptoms. It prevents the peripheral breakdown of levodopa, increasing its availability to the central nervous system.
The dosing of carbidopa is entirely dependent on the dose of levodopa it is paired with. For most patients, a minimum of 70 mg to 100 mg of carbidopa per day is required to adequately inhibit the peripheral DOPA decarboxylase enzyme.
The safety and effectiveness of carbidopa in pediatric patients (under the age of 18) have not been established. Parkinson's disease is predominantly a condition of older adults. If a child requires carbidopa for a rare metabolic condition, it is considered an 'orphan' or off-label use and must be managed by a specialist in pediatric neurology or genetics.
There are no specific FDA-mandated dose adjustments for patients with kidney disease. However, because a significant portion of the drug is excreted renally, healthcare providers should monitor patients with severe renal impairment (GFR < 30 mL/min) closely for signs of toxicity or increased side effects.
Carbidopa metabolism is not primarily hepatic; however, since levodopa metabolism can be affected by liver function, patients with significant liver disease should be monitored for changes in drug efficacy and safety.
Most clinical trials for carbidopa involved patients over 65. No specific dose adjustments are required based solely on age, but elderly patients are more susceptible to the orthostatic hypotension (dizzy spells upon standing) and hallucinations associated with increased dopamine levels.
If you miss a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not double the dose to catch up. Missing doses can cause a rapid return of Parkinson's symptoms, known as 'freezing.'
Signs of a carbidopa/levodopa overdose include severe muscle twitching, eyelid spasms (blepharospasm), rapid heartbeat (tachycardia), extreme confusion, or agitation. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment is generally supportive, focusing on cardiovascular monitoring and airway protection.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance, as changing the carbidopa-to-levodopa ratio can significantly impact your motor control.
Because carbidopa is almost always taken with levodopa, most side effects are the result of increased dopamine levels in the body. Common experiences include:
Carbidopa is a potent modifier of neurotransmitter metabolism. It must be used under strict medical supervision. Patients should be aware that while carbidopa reduces the peripheral side effects of levodopa, it may actually increase the central nervous system side effects (like hallucinations or dyskinesia) because it allows more levodopa to reach the brain.
No FDA black box warnings for Carbidopa.
FDA Pregnancy Category C. Animal studies have shown that carbidopa and levodopa can cause visceral and skeletal malformations in rabbits. There are no adequate, well-controlled studies in pregnant women. Carbidopa should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is generally avoided in the first trimester unless absolutely necessary for maternal mobility.
It is not known whether carbidopa is excreted in human milk. However, levodopa is known to inhibit lactation by suppressing prolactin secretion. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Carbidopa is not approved for use in children under 18. Parkinson's disease is exceptionally rare in this population. In cases of 'Juvenile Parkinsonism,' which is usually genetic, carbidopa use is considered experimental and must be managed by specialized pediatric centers.
Carbidopa is a white, crystalline compound that is an inhibitor of aromatic amino acid decarboxylation. Its molecular mechanism involves the competitive inhibition of the enzyme L-aromatic amino acid decarboxylase (DDC). This enzyme is responsible for the decarboxylation of L-dopa to dopamine, L-5-hydroxytryptophan to serotonin, and L-histidine to histamine.
By binding to DDC in the peripheral tissues (gut, liver, kidneys), carbidopa prevents the conversion of levodopa to dopamine before it reaches the brain. This is critical because dopamine in the periphery cannot cross the blood-brain barrier and causes systemic side effects. Carbidopa's lack of a 'transport moiety' prevents it from crossing the blood-brain barrier itself, ensuring that DDC remains active within the central nervous system to convert levodopa into the needed dopamine.
The pharmacodynamic effect of carbidopa is purely 'permissive.' It has no intrinsic activity on dopamine receptors and does not improve Parkinson's symptoms if given alone. Its duration of effect is linked to its enzyme-binding affinity, which typically lasts for 4-6 hours, necessitating multiple daily doses. Tolerance to the decarboxylase inhibition does not typically develop, though the brain's response to the resulting dopamine changes over time (leading to dyskinesias).
Common questions about Carbidopa, Levodopa, And Entacapone
Carbidopa is primarily used as an adjunct medication to treat the symptoms of Parkinson's disease and parkinsonism. It is not effective on its own and must be taken with levodopa to work correctly. Its main job is to prevent the breakdown of levodopa in the bloodstream, ensuring more medicine reaches the brain. This allows for lower doses of levodopa and reduces side effects like severe nausea and vomiting. Healthcare providers may also use it for post-encephalitic parkinsonism or symptoms following carbon monoxide poisoning. Always use this medication exactly as prescribed by your neurologist.
Since carbidopa is taken with levodopa, the most common side effects are related to increased dopamine levels. These include nausea, dizziness, lightheadedness, and dry mouth. Many patients also experience involuntary movements known as dyskinesia, which can look like twitching or swaying. Some people report vivid dreams or difficulty sleeping when first starting the medication. Most of these side effects can be managed by adjusting the dose or timing of the medication. If you experience severe hallucinations or chest pain, you should contact your doctor immediately.
It is generally recommended to avoid or strictly limit alcohol consumption while taking carbidopa and levodopa. Alcohol can enhance the side effects of the medication, such as dizziness, drowsiness, and lightheadedness. This significantly increases the risk of accidental falls, which can be particularly dangerous for Parkinson's patients. Alcohol may also interfere with the effectiveness of the drug in controlling motor symptoms. If you choose to drink, do so only in moderation and after discussing the risks with your healthcare provider. Never drive after consuming alcohol while on this medication.
Carbidopa is classified as FDA Pregnancy Category C, meaning its safety in humans has not been fully established. Animal studies have shown potential risks to the developing fetus, including skeletal malformations. Because of this, it is only prescribed during pregnancy if the benefits to the mother's mobility clearly outweigh the risks to the baby. There is also very little data on whether the drug passes into breast milk, and it may interfere with a mother's ability to produce milk. If you are pregnant or planning to become pregnant, a detailed discussion with your neurologist and obstetrician is necessary. Most doctors recommend using the lowest effective dose if treatment is required.
The effects of carbidopa on preventing nausea occur almost immediately with the first few doses. However, the full therapeutic benefit for Parkinson's symptoms (when taken with levodopa) may take several weeks to become apparent. Your doctor will likely start you on a low dose and gradually increase it, a process called titration. You might notice improvements in your ability to move and a reduction in tremors within the first week, but fine-tuning the dose for maximum benefit often takes months. It is important to be patient and maintain a consistent dosing schedule during this time. Notify your doctor if you do not see any improvement after several weeks.
No, you should never stop taking carbidopa or levodopa suddenly. Abruptly discontinuing this medication can lead to a dangerous condition called Neuroleptic Malignant Syndrome (NMS). Symptoms of NMS include very high fever, severe muscle rigidity, confusion, and unstable blood pressure, which can be life-threatening. If the medication needs to be stopped, your doctor will provide a schedule to slowly taper the dose down. Sudden stopping can also cause a 'rebound' of Parkinson's symptoms, making it impossible to move or swallow safely. Always consult your healthcare provider before making any changes to your medication regimen.
If you miss a dose of carbidopa, take it as soon as you remember to maintain consistent levels in your body. However, if it is almost time for your next scheduled dose, skip the missed one and continue with your regular routine. Do not take two doses at once to make up for a missed one, as this can increase the risk of side effects like dyskinesia or hallucinations. Missing doses can cause your Parkinson's symptoms to return quickly, often referred to as 'off' periods. Setting an alarm or using a pill organizer can help you stay on track. If you miss multiple doses, contact your doctor for advice.
Weight gain is not a common side effect of carbidopa; in fact, weight loss is more frequently reported. Some patients experience a loss of appetite or nausea, which can lead to eating less. However, in some cases, if the medication successfully treats depression associated with Parkinson's, a patient might see an increase in appetite. Additionally, the involuntary movements (dyskinesia) caused by the medication can burn a significant number of calories, leading to weight loss over time. If you notice significant, unexplained changes in your weight, discuss them with your healthcare provider. They can help determine if the change is due to the medication or the progression of the disease.
Carbidopa can interact with several other medications, so a full review of your current drugs is essential. It should never be taken with non-selective MAO inhibitors, as this can cause a dangerous spike in blood pressure. Antipsychotic drugs and certain anti-nausea medications (like metoclopramide) can block the effects of carbidopa and worsen Parkinson's symptoms. Iron supplements can also prevent the drug from being absorbed properly if taken at the same time. Blood pressure medications may need to be adjusted because carbidopa can cause dizziness upon standing. Always provide your doctor and pharmacist with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you use.
Yes, carbidopa is available as a generic medication, both as a stand-alone tablet (generic Lodosyn) and in combination with levodopa. Generic versions are required by the FDA to have the same active ingredients, strength, and effectiveness as the brand-name versions. Choosing the generic version can significantly reduce the cost of long-term Parkinson's treatment. Most insurance plans and Medicare cover the generic forms of carbidopa/levodopa. If you have concerns about switching from a brand-name to a generic, discuss them with your pharmacist or doctor. They can ensure that the specific formulation you receive is appropriate for your needs.
Other drugs with the same active ingredient (Carbidopa)
> Warning: Stop taking Carbidopa and call your doctor immediately if you experience any of these serious symptoms:
With prolonged use (typically 3-5 years), many patients experience the 'Wearing-Off' Phenomenon. This occurs when the medication's effect fades before the next dose is due. Additionally, patients may experience the 'On-Off' Phenomenon, where the drug's effectiveness switches on and off unpredictably. Long-term use is also associated with permanent dyskinesias (involuntary movements) that may require surgical interventions like Deep Brain Stimulation (DBS).
No FDA black box warnings for Carbidopa. However, it carries significant 'Precautions and Warnings' regarding its use in patients with a history of melanoma or undiagnosed skin lesions, as early studies suggested a possible link between levodopa/carbidopa and the progression of skin cancer (though recent data suggests the disease itself may increase risk, not the drug).
Report any unusual symptoms to your healthcare provider. Monitoring for skin changes and psychological shifts is a standard part of long-term Carbidopa therapy.
Healthcare providers typically require the following monitoring for patients on long-term carbidopa therapy:
Carbidopa/levodopa can cause 'sleep attacks'—sudden onset of sleep without prior warning. Patients have reported falling asleep while driving, which can lead to fatal accidents. Until you know how this medication affects you, avoid driving or operating heavy machinery. If you experience significant daytime sleepiness, notify your doctor immediately.
Alcohol should be avoided or strictly limited. Alcohol can worsen the sedative effects of the medication and increase the risk of dizziness, fainting, and falls. It may also interfere with the motor benefits of the drug.
Never stop taking carbidopa abruptly. Rapid withdrawal or a sharp reduction in dose can lead to a symptom complex resembling Neuroleptic Malignant Syndrome (NMS). Symptoms include muscle stiffness, high fever, rapid breathing, and mental confusion. If the drug must be stopped, it must be tapered slowly under a doctor's guidance.
> Important: Discuss all your medical conditions, especially heart, lung, kidney, or psychiatric issues, with your healthcare provider before starting Carbidopa.
Carbidopa/levodopa can cause false-positive results in urine ketone tests (using dipsticks). It may also result in a false-positive Coombs test (used to detect anemia) and can occasionally interfere with tests for uric acid or glucose.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete list is vital to prevent dangerous interactions.
There is no known cross-sensitivity between carbidopa and other non-dopaminergic drug classes. However, patients who have had severe adverse reactions to other DOPA decarboxylase inhibitors (though few exist outside this class) should proceed with extreme caution.
> Important: Your healthcare provider will evaluate your complete medical history, including your eye health and skin history, before prescribing Carbidopa.
This is the primary population for carbidopa. While effective, elderly patients are at a significantly higher risk for:
Lower starting doses and slower titration are often recommended for the 'frail elderly.'
Patients with a GFR below 30 mL/min should be monitored for signs of accumulation. While no specific formula for dose reduction exists, clinical response should dictate the frequency of dosing. Dialysis does not significantly clear carbidopa, so supplemental doses after dialysis are usually not required.
In patients with Child-Pugh Class B or C hepatic impairment, the metabolism of the amino acids may be slowed. These patients should be monitored for increased sedation and motor fluctuations. Liver enzymes should be checked every 3-6 months.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are planning to become pregnant or have existing organ impairment.
| Parameter | Value |
|---|---|
| Bioavailability | 40% - 70% |
| Protein Binding | ~36% |
| Half-life | 2 hours |
| Tmax | 0.5 to 2 hours |
| Metabolism | Non-CYP; Metabolized to hydrazine derivatives |
| Excretion | Renal 35%, Fecal 10-15% |
Carbidopa belongs to the class of Aromatic Amino Acid Decarboxylation Inhibitors. It is unique in this class as the only widely used peripheral inhibitor for Parkinson's. It is chemically related to methyldopa (an antihypertensive), but unlike methyldopa, it does not have significant blood-pressure-lowering effects at standard doses.